Moderna is pioneering a new class of drugs, the messenger RNA Therapeutics (mRNAs), with the potential to treat a wide range of diseases and conditions. Moderna developed a vaccine against COVID-19 for which Swissmedic granted a temporary marketing authorization on 12 January 2021 under the name „COVID-19 Vaccine Moderna” following the scientific assessment of Swissmedic.

More from Kellerhals Carrard